Current Cardiology Reviews

Current Cardiology Reviews is a bimonthly review journal from Bentham Science Publishers, launched in 2005 and given over almost entirely to synthesis of the cardiology literature rather than to new experiments.《当前心脏病学评论》由 Bentham Science Publishers 出版，2005 年创刊，双月刊，整本刊物几乎全部篇幅用于梳理心脏病学文献，原创实验论文不在常规体裁之内。

Each issue carries full-length reviews, mini-reviews and guest-edited thematic collections built around a single subject. The 2025 Journal Citation Reports give it a JIF of 2.4 and Q2 standing at 117 of 237.每期登载长篇综述、短篇小型综述与客座主编的专题组稿，2025 年期刊引证报告给出的影响因子为 2.4，在心脏与心血管系统类排到 Q2，位次是 237 种期刊中的第 117 位。

Scope

• The remit is set out in a single sentence on the publisher's site, naming full-length reviews, mini-reviews and guest-edited thematic issues on the latest advances in cardiovascular physiology and physiopathology.出版方用一句话写定收录范围，列出长篇综述、小型综述与客座主编的专题组稿，主题限于心血管生理学与病理生理学的最新进展。
• The rest of that sentence turns to practice, covering the clinical approach to diagnosing and treating cardiovascular disease, prevention, cardiac surgery and transplantation, a span from bench to ward.同一句话的后半段转向临床，心血管疾病的诊断与治疗路径，疾病预防，心脏外科与移植并列其内，从实验台到病房的距离被写进了宗旨。
• Arrhythmia heads the topic list on the manuscript portal, taking in electrophysiology, catheter ablation, atrial fibrillation and the long-term care of patients who live with rhythm disorders.心律失常排在这份选题清单的首位，涵盖电生理、导管消融与心房颤动，还包括心律异常患者的长期照护。
• Congestive heart failure gets steady coverage, running from ejection fraction phenotypes and biomarker screening through device therapy to the organisation of follow-up after a decompensation in hospital.充血性心力衰竭占去稳定篇幅，从射血分数分型与生物标志物筛查，一路写到器械治疗，再写到住院失代偿之后的随访安排。
• Cardiomyopathy and congenital heart disease are handled side by side, with inherited muscle disease and the grown-up survivors of childhood repair both sitting inside those two headings.心肌病与先天性心脏病并列处理，遗传性心肌病变，幼年矫治后存活至成年的患者，都落在这两个名目之下。
• Drug therapy is a standing heading, covering antiplatelet and anticoagulant regimens, lipid-lowering agents, heart failure pharmacotherapy and the interaction between cardiac drugs and comorbidity treatment in older patients.药物治疗是常设方向，涉及抗血小板与抗凝方案，降脂药物，心力衰竭的用药，以及老年患者身上心脏病药物与合并症用药之间的相互影响。
• Methodology and cardiac testing form another strand, where stress testing, echocardiography, nuclear imaging, computed tomography and biomarker assay are weighed against one another for diagnostic yield and cost.方法与心脏检查构成另一条线索，负荷试验，超声心动图，核素显像，计算机断层扫描与生物标志物检测，按诊断收益与费用彼此权衡。
• Pacing and devices get their own place, from pacemakers and implantable defibrillators to stents, transcatheter valves and the remote monitoring that follows a patient home after implantation.起搏与器械单列一块，从起搏器与植入式除颤器，到支架、经导管瓣膜，再到植入之后随访患者的远程监测。
• Preventive cardiology closes the clinical list, taking in risk scores, hypertension and lipid management, smoking cessation and the population strategies written into the international guideline targets of the field.预防心脏病学收束这份临床清单，涵盖风险评分，高血压与血脂管理，戒烟，以及写进国际指南目标值的人群策略。
• Basic physiology and physiopathology carry equal weight in the brief, since mechanism reviews on myocardial energetics, vascular remodelling, inflammation, fibrosis and ischaemic injury give the clinical papers their footing.基础生理学与病理生理学份量相当，心肌能量代谢，血管重塑，炎症与纤维化，以及缺血损伤的机制综述，为临床论文提供落脚点。
• Two lengths of review are printed. A full-length article runs over the whole evidence base for a question, while a mini-review takes a narrow update and makes its point in far fewer pages.综述分两种篇幅，长篇综述把一个问题的证据基础整个过一遍，小型综述只取一处较窄的更新，用少得多的版面把话说完。
• Thematic issues are the third format, an entire number given to one subject under a guest editor and built around a single clinical or mechanistic question of the field.专题组稿是第三种体裁，一整期交给一位客座主编，围绕本领域一个临床问题或机制问题搭建。
• Readers are general cardiologists, subspecialty fellows and internists who need the state of a question without reading forty primary papers, which is why the prose stays expository rather than statistical.读者是普通心内科医师、亚专科进修医师与内科医师，他们要知道某个问题的现状，却不必读完四十篇原始论文，行文因此保持说明性而非统计性。
• Because no primary data are reported, the value of a paper rests on how well it frames the trial evidence and where it draws the line between established practice and conjecture.由于不报告原始数据，一篇论文的价值取决于它对试验证据的框定是否妥当，以及它在成熟做法与推测之间划线是否清楚。

History

• The first issue appeared in January 2005 as volume 1, number 1, from Bentham Science Publishers, a publishing house then still sharing an imprint between Sharjah and San Francisco, California.创刊号于 2005 年 1 月问世，编为第 1 卷第 1 期，出版方是 Bentham Science Publishers，当时这家出版社的出版地还并署沙迦与旧金山两地。
• That double imprint survives in the National Library of Medicine record, which gives the place of publication as Saif Zone, Sharjah, with San Francisco, California, carried as a second city.这条并署至今留在美国国家医学图书馆的书目里，出版地写作沙迦的 Saif Zone，旧金山（California）作为第二城市保留在册。
• The library classifies the title under the publication type Review, and its single MeSH heading is cardiovascular diseases, which frames what the editors have always been asked to cover.该馆把本刊归入综述（Review）这一出版类型，主题词只有心血管疾病一条，编辑们被要求覆盖的范围由此定格。
• Frequency has moved twice. Three issues came out in 2005 in a single volume, four a year followed from 2006 through 2020, and a bimonthly rhythm of six issues began in 2021.刊期改动过两次，2005 年出了三期，2006 年至 2020 年每年四期，2021 年起改为双月刊，每年六期。
• One volume is completed each year without exception, so the 2025 issues sit in volume 21, and the publisher still describes the title as appearing in print and online.每年整卷出齐，没有例外，2025 年的各期落在第 21 卷，出版方至今仍写明本刊以纸本与网络两种形式发行。
• The name itself has never changed, although the library keeps an alternate title, Cardiology Reviews, a short form that appears in some early citations and catalogue entries.刊名本身从未改动，只是该馆另存了一个交替题名 Cardiology Reviews，这个简称见于少量早期引文与目录著录。
• PubMed picked the title up at volume 4 in 2008, while MEDLINE waited until volume 7, number 2, in May 2011, a gap of three years between the two major indexing services.PubMed 从 2008 年的第 4 卷起收录，MEDLINE 则等到 2011 年 5 月的第 7 卷第 2 期，两项服务之间隔了三年。
• Full text has also been deposited in PubMed Central, which gives the review articles a second home outside the subscription platform and keeps older issues reachable without a licence.全文同时存入 PubMed Central，综述文章因此在订阅平台之外有了第二个落点，旧各期对没有订阅权限的读者也能打开。
• The journal is listed in the Emerging Sources Citation Index rather than the Science Citation Index Expanded, a distinction that matters to authors whose institutions count only the latter.本刊收录于 Emerging Sources Citation Index，并不在 Science Citation Index Expanded 之内，对只认后者的机构作者而言，这条差别有实际分量。
• Impact has been flat rather than rising across the last three reports. The 2023 figure was 2.4, 2024 brought 2.2, and 2025 returned to 2.4, with a five-year value of 4.0 sitting behind those annual scores.影响因子走平，没有爬升。2023 年为 2.4，2024 年落到 2.2，2025 年回到 2.4，三个年度数值背后是 4.0 的五年影响因子。
• Output is small by design. The 2025 citation window counted seventeen citable items against 2606 citations, and a cited half-life of 6.6 years is long for a clinical field of this size.发文量按体例压得很小，2025 年被引窗口内的可被引文献只有 17 篇，累计被引 2606 次，6.6 年的被引半衰期在临床领域算长。
• Open access is the exception. About 6.4 per cent of recent articles were published gold open access, and the rest sit behind the subscription wall of the publisher carried since 2005.开放获取属于例外，近年约 6.4% 的文章以金色开放获取发表，其余仍留在订阅墙之内，这道墙从 2005 年起就立着。

Editors

• Tong Liu holds the editor-in-chief post, listed by the publisher in the Department of Cardiology at the Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.主编由 Tong Liu 担任，出版方把他的任职单位写作天津医科大学第二医院心脏内科，同时挂 Tianjin Institute of Cardiology。
• Buddhadeb Dawn of the Department of Internal Medicine at the University of Nevada, Las Vegas, is listed as associate editor, working with the editor-in-chief on the flow of submitted reviews.副主编由内华达大学拉斯维加斯分校（University of Nevada Las Vegas）内科系的 Buddhadeb Dawn 担任，与主编一同经手来稿的流转。
• The masthead is layered. It runs from the editor-in-chief through associate editors, a regional editor and section editors to a frontiers section editor, board members and associate board members.编委会分层设置，自上而下是主编，副主编，地区编辑，栏目编辑，再往下是前沿栏目编辑、编委与副编委。
• Board members are drawn from several continents. Erick Alexanderson, for instance, is listed with the Department of Nuclear Cardiology at the National Institute of Cardiology in Mexico City.编委来自多个大洲，Erick Alexanderson 的条目挂在墨西哥城国家心脏病研究所（National Institute of Cardiology）核医学心脏病科名下。
• Because the journal publishes reviews, editorial judgement turns on whether a synthesis is complete and current, not on whether a raw dataset holds up.刊物以综述为主体，编辑取舍看的是梳理是否完整、是否跟得上进展，原始数据能否复现不属于评审项目。
• Every manuscript meets a scope check first. Editors decide whether a submission belongs in the journal themselves or with advice from other specialists before any reviewer is approached.每份稿件先过一道范围审查，编辑或凭自身判断、或另请同行出主意，决定稿件是否属于本刊，之后才去找审稿人。
• Independent review follows on every paper the publisher accepts for consideration, a policy written out on the journal's own peer review workflow page rather than left implicit.通过初筛的稿件一律送独立评审，这条政策写在刊物自己的同行评审流程页上，没有留作默认。
• Section editors carry weight in practice. Issue prefaces thank them by name alongside the associate editors and board, crediting their guidance as a reason the series has grown.栏目编辑实际分量不轻，各期前言会点名致谢，与副主编和编委并列，并把这些指导写成刊物得以成长的一个缘由。
• Guest editors build the single-topic issues, an arrangement named in the scope statement, and a guest usually writes the preface that opens the collection for the number.专题期由客座主编搭起来，这一安排在宗旨里写明，开篇前言通常也由这位客座主编执笔。
• Manuscripts go through the publisher's own portal at bentham.manuscriptpoint.com, where the journal keeps a page listing the topic headings, the review formats and the editorial contacts.稿件经出版方自建的投稿系统递交，本刊在该系统里有独立页面，列着选题方向、综述体裁与编辑部联系方式。